In the company’s news yesterday,
MDRNA, Inc. announced that it has entered into a licensing agreement with Novartis for MDRNA’s liposomal technology platform for siRNA delivery. According to the press release, MDRNA will receive $7.25 million in upfront fees for the non-exclusive license. The companies also entered into a separate agreement that provides Novartis with an exclusive period to negotiate a research and development collaboration and broader licensing rights related to MDRNA’s RNAi drug delivery platform.
J. Michael French, President and Chief Executive Officer of MDRNA, stated, “We are pleased to enter into this agreement with Novartis, a global leader in the field of RNAi-based therapeutics. MDRNA’s DiLA2 technology for siRNA delivery is effective and efficient at silencing gene targets in the liver and jejunum. Further, the in vivo tolerability of the DiLA2 technology is excellent.”
He added, “We have not observed any delivery related adverse effects in the liver as measured by typical serum chemistries or any significant increases in cytokine levels, which are hallmarks of cell damage. We view this license as yet another important validation of our siRNA technologies and we look forward to a strong and growing relationship with Novartis.”
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
